A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Allergan

Status: Completed

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Treatments: Drug: Bimatoprost Ophthalmic Solution

Study type: Observational

Funder types: Industry

Identifiers

NCT01853085

MAF/AGN/OPH/GLA/038

Details and patient eligibility

About

The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.

Enrollment: 1,830 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with primary open-angle glaucoma or ocular hypertension
• Previously prescribed intraocular pressure (IOP)-lowering medication with insufficient IOP control and is now being switched to Lumigan® UD for medical reasons

Exclusion criteria

• None

Trial design

1,830 participants in 1 patient group

Patients with POAG or OHT

Description:

Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.

Treatment:

Drug: Bimatoprost Ophthalmic Solution